InkVivo Technologies secures CHF 1.1 million in pre-seed funding to advance polymer drug delivery platform

InkVivo Technologies, a Swiss spin-off from ETH Zurich now incubated at USI Startup Centre in Lugano, has taken a bold stride in biotech innovation. With CHF 1.1 million raised in a pre-seed round, the company is well-positioned to deepen its clinical development efforts and accelerate commercialization of its groundbreaking drug delivery systems.

InkVivo Technologies has successfully closed a CHF 1.1 million pre-seed financing round, spearheaded by TiVentures and Claves Investments, with contributions from strategic angel investors. The capital will be used to advance the company's clinical development of its state-of-the-art polymer-based drug delivery formulations and to broaden its product pipeline across therapeutic areas.

The startup's core technology leverages a patented biomaterial platform and advanced manufacturing techniques—including precise 3D design—to create localized, time-controlled release of active ingredients. Initially aimed at gastroretentive systems for anemia and obesity, InkVivo plans to expand its applications to nutraceuticals, oncology, metabolic disorders such as Type 2 diabetes, and beyond.

“This round marks an important step for InkVivo’s mission to unlock the full therapeutic potential of active ingredients through smart formulations. Our platform allows us to rethink how medicines are delivered, replacing frequent dosing and poor absorption with solutions that are more effective, longer-lasting, and easier for patients. At the same time, we help industry partners reformulate drugs faster, extend product life cycles, and unlock new IP opportunities. With this funding, we are advancing our lead product targeting anemia and scaling up new collaborations with pharmaceutical partners,” says Elia Guzzi, CEO & Co-Founder.

InkVivo is a Venture Kick alumni, participated in Venture Leaders Biotech in 2025, and ranked at the TOP 100 Swiss Startup Award in 2023 and 2024.

InkVivo Technologies co-founders, CEO Dr. Elia Guzzi and COO Stefano Cerutti